Neurological abnormalities specialist Wave Neuroscience said on Thursday that it has closed the brain treatment technology asset purchase agreement with Newport Brain Research Laboratory (NBRL) for an undisclosed amount.
Under the terms of the agreement, Wave Neuroscience purchased substantially all of the assets from the various onshore and offshore holding companies under NBRL.
In conjunction with the acquisition, key NBRL personnel were appointed to new roles at Wave Neuroscience.
Since June, Wave Neuroscience has pledged more than USD500,000 of free treatments to US military members.
According to Wave Neuroscience, its research revolves around the premise that the brain can be treated by non-pharmaceutical and non-surgical means. It offers a personalised treatment platform for addressing neurological abnormalities and has treated more than 7,000 patients using its patented, non-invasive, drug-free MeRT process, which is licensed by a network of independently owned medical facilities.
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD